Caveolin-1 Modulation Increases Efficacy of a Galacto-Conjugated Phthalocyanine in Bladder Cancer Cells Resistant to Photodynamic Therapy.
Aged
Blotting, Western
Caveolin 1
/ genetics
Cell Line, Tumor
Endocytosis
/ drug effects
Female
Galectin 1
/ genetics
Galectin 3
/ genetics
Glucose Transporter Type 1
/ genetics
Humans
In Vitro Techniques
Indoles
/ chemistry
Isoindoles
Male
Microscopy, Fluorescence
Photochemotherapy
/ methods
Urinary Bladder Neoplasms
/ metabolism
GLUT1
bladder cancer
caveolae
endocytosis
photodynamic therapy
Journal
Molecular pharmaceutics
ISSN: 1543-8392
Titre abrégé: Mol Pharm
Pays: United States
ID NLM: 101197791
Informations de publication
Date de publication:
01 06 2020
01 06 2020
Historique:
pubmed:
28
4
2020
medline:
8
6
2021
entrez:
28
4
2020
Statut:
ppublish
Résumé
Photodynamic therapy (PDT) has demonstrated encouraging anticancer therapeutic results, but the current clinically approved photosensitizers (PSs) are not ideal in the treatment of bladder cancer. Conventional PSs have low selectivity to the bladder tumor tissue and induce toxicity or bystander effects on nontumor urothelium. Previous studies demonstrated that the use of galactose-photosensitizer (PS) conjugates is a more selective method of delivering PDT-mediated toxicity due to their ability to recognize carbohydrate-binding domains overexpressed in bladder tumors. Using patient-derived bladder tumor specimens cultured
Identifiants
pubmed: 32339462
doi: 10.1021/acs.molpharmaceut.0c00298
doi:
Substances chimiques
Caveolin 1
0
Galectin 1
0
Galectin 3
0
Glucose Transporter Type 1
0
Indoles
0
Isoindoles
0
SLC2A1 protein, human
0
phthalocyanine
V5PUF4VLGY
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM